2022-01-17| ChinaCOVID-19

Shanghai’s Everest Medicines Licenses COVID-19 Oral Antivirals from Singapore’s National Drug Discovery Platform

by Joy Lin
Share To

Shanghai-based Everest Medicines has obtained a global license for a series of oral antivirals from Singapore’s Experimental Drug Development Centre (EDDC), the country’s drug discovery platform. The drugs, which inhibit viral 3C-like (3CL) protease, have shown potent in vitro activity against viruses that cause Covid-19 and MERS.  

The license includes full technology transfer and gives Everest the right to develop, produce and sell the drugs. It also allows Everest to further sub-license the drugs to other companies. 

Under the deal, Everest will pay the EDDC an undisclosed sum upfront, as well as future milestones and net royalties on net product sales. 

Related Article: Singapore Becomes Latest Asian Country to Sign Merck Deal for Oral COVID-19 Pill

How Do 3CL Protease Inhibitors Work? 


The most famous example of a 3CL protease inhibitor is perhaps nirmatrelvir, one half of Pfizer’s FDA-approved nirmatrelvir/ritonavir combo, a.k.a. Paxlovid. 

The class of drugs mainly work by preventing viral replication through the inhibition of 3CL protease, the main protease in coronaviruses that processes polyproteins translated from viral RNA. 

According to a press release, Everest claimed that the lead compound it is in-licensing, EDDC-2214, exhibits better in-vitro potency and preclinical oral bioavailability over “several other antivirals”. The company has said that it plans to take EDDC-2214 into clinical trials later this year. 

Everest CEO Kerry Blanchard noted that EDDC-2214 and other 3CL protease inhibitors will complement the company’s Covid-19 vaccine program. Everest is developing Covid-19 mRNA vaccines in collaboration with Canada-based Providence Therapeutics. The companies last December received approval for their shot to be included in the WHO-sponsored Solidarity Trial Vaccines program. 

Related Article: Pfizer’s COVID-19 Oral Antiviral Cuts Hospitalization and Death By 89%

EDDC, Singapore’s National Drug Discovery Platform


The EDDC is Singapore’s national drug discovery and development platform, hosted by the Agency for Science, Technology and Research (A*STAR). 

The centre focuses on developing treatments and vaccines for infectious diseases. EDDC has collaborated with public sector agencies to develop neutralizing antibodies against Covid-19. 

During the outbreak of H1N1 influenza A virus around the world, the EDDC partnered with public and private organizations to launch Singapore’s first H1N1 influenza vaccine. 

The EDDC also teamed up with Visterra Inc, a US biotech, to develop a monoclonal antibody against the dengue virus called VIS513. The antibody, along with Visterra’s entire pipeline, was acquired by Otsuka Pharmaceutical, a Japanese firm, for $430 million in 2018.  

Related Article: Shionogi and Ildong Team up to Co-Develop Oral COVID-19 Pill

© All rights reserved. Collaborate with us:
Related Post
Learning From the COVID-19 Pandemic With Moderna CEO, Stéphane Bancel
Genetics May Be a Factor in Varying COVID-19 Severity
Pfizer to Address COVID-19 Reinfection After Paxlovid Treatment
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
Stanford Touts Remote-Controllable CAR-T Cell Therapy
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
ASCO Annual Meeting
Online and on-side
Digital RESI June
BIO International Convention
San Diego, CA
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!